Literature DB >> 420547

Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse.

C Kornetsky, R U Esposito, S McLean, J O Jacobson.   

Abstract

We present the thesis that many drugs of abuse are used for their hedonic effects and that a relevant animal model for the study of these effects is the action of these drugs on the pathways that support rewarding intracranial self-stimulation. A relationship between abuse potential of a drug and its ability to lower the threshold for rewarding brain stimulation in the rat was found. Of all the compounds we have studied, morphine and cocaine were the drugs that caused the maximum lowering of the rewarding threshold. Phencyclidine hydrochloride and the mixed agonist-antagonist pentazocine also lowered the threshold to a lesser degree, while the mixed agonist-antagonists cyclazocine and nalorphine hydrochloride had inconsistent effects. Naloxone hydrochloride, at the doses tested, had no effect on the threshold. Further, there is no evidence that tolerance develops to the threshold-lowering effect of morphine, suggesting that continued use of narcotics by the physically dependent individual is not simply due to an effort to avoid the pain of withdrawal.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 420547     DOI: 10.1001/archpsyc.1979.01780030055004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  51 in total

1.  Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats.

Authors:  Svetlana Semenova; Daniel Hoyer; Mark A Geyer; Athina Markou
Journal:  Neuropeptides       Date:  2010-10       Impact factor: 3.286

Review 2.  The neurocircuitry of addiction: an overview.

Authors:  M W Feltenstein; R E See
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

3.  Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

4.  Status and Future Directions of Preclinical Behavioral Pharmacology in Tobacco Regulatory Science.

Authors:  Mark G LeSage; John R Smethells; Andrew C Harris
Journal:  Behav Anal (Wash D C)       Date:  2018-07-09

5.  CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP.

Authors:  Riccardo Dore; Attilio Iemolo; Karen L Smith; Xiaofan Wang; Pietro Cottone; Valentina Sabino
Journal:  Neuropsychopharmacology       Date:  2013-05-09       Impact factor: 7.853

6.  Adolescent intermittent ethanol exposure diminishes anhedonia during ethanol withdrawal in adulthood.

Authors:  Nathalie Boutros; Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2014-02-04       Impact factor: 4.600

7.  Synthetic cathinones and their rewarding and reinforcing effects in rodents.

Authors:  Lucas R Watterson; M Foster Olive
Journal:  Adv Neurosci (Hindawi)       Date:  2014-06-04

8.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

9.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

10.  Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats.

Authors:  M G LeSage; M Staley; P Muelken; J R Smethells; I Stepanov; R I Vogel; P R Pentel; A C Harris
Journal:  Drug Alcohol Depend       Date:  2016-09-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.